Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

Next Previous
Trial Profile

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paltusotine (Primary)
  • Indications Malignant carcinoid syndrome; Neuroendocrine tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms CAREFNDR
  • Sponsors Crinetics Pharmaceuticals

Most Recent Events

  • 25 Jul 2025 Status changed from planning to recruiting.
  • 27 Feb 2025 According to a Crinetics Pharmaceuticals media release, enrollment of the first patient in the pivotal Phase 3 trial of paltusotine in carcinoid syndrome is anticipated in the second quarter of 2025.
  • 12 Nov 2024 According to a Crinetics Pharmaceuticals media release, company expects to finalize a Phase 3 protocol and initiate site startup activities for its investigational drug paltusotine in carcinoidsyndrome by the end of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top